Intellia Therapeutics (NTLA) announced positive Phase 2 data from the ongoing Phase 1/2 study of NTLA-2002 in patients with hereditary angioedema, HAE, with results continuing to indicate that NTLA-2002 has the potential to eliminate HAE attacks following a one-time infusion. Results were published online today in The New England Journal of Medicine and will be presented on Saturday, October 26 at the 2024 American College of Allergy, Asthma & Immunology, ACAAI, Scientific Meeting in Boston, Massachusetts. Deep attack rate reductions achieved in both dose levels tested; a single 50 mg dose resulted in a mean monthly attack rate reduction of 77% and 81% compared to placebo during weeks 1-16 and 5-16, respectively. Eight of 11 patients in the 50 mg arm were completely attack free following a one-time infusion through the latest follow-up; data support NTLA-2002’s potential to be a functional cure for hereditary angioedema.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Cathie Wood’s ARK Investment bought 162K shares of Intellia Therapeutics today
- Cathie Wood’s ARK Investment bought 44K shares of Intellia Therapeutics today
- Stifel says early WVE-006 data de-risks DNA editing approaches like Beam’s ‘302
- Intellia Therapeutics announces new date for investor webcast
- Intellia Therapeutics announces initiation of HAELO Phase 3 study